AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balaban, N.
Right arrow Articles by Mor, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balaban, N.
Right arrow Articles by Mor, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2004, p. 2544-2550, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2544-2550.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

A Chimeric Peptide Composed of a Dermaseptin Derivative and an RNA III-Inhibiting Peptide Prevents Graft-Associated Infections by Antibiotic-Resistant Staphylococci

Naomi Balaban,1* Yael Gov,1 Andrea Giacometti,2 Oscar Cirioni,2 Roberto Ghiselli,3 Federico Mocchegiani,3 Fiorenza Orlando,4 Giuseppina D'Amato,2 Vittorio Saba,3 Giorgio Scalise,2 Sabina Bernes,5 and Amram Mor5*

Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv,1 Laboratory of Antimicrobial Peptides Investigation, Department of Food Engineering & Biotechnology, Technion-Israel Institute of Technology, Haifa 32000, Israel, and,5 Institute of Infectious Diseases and Public Health,2 Department of General Surgery, I.N.R.C.A., I.R.R.C.S., University of Ancona,3 Research Department, Biotechnology Center, I.N.R.C.A., I.R.R.C.S., Ancona, Italy4

Received 2 May 2003/ Returned for modification 6 October 2003/ Accepted 24 December 2003

Staphylococcal bacteria are a prevalent cause of infections associated with foreign bodies and indwelling medical devices. Bacteria are capable of escaping antibiotic treatment through encapsulation into biofilms. RNA III-inhibiting peptide (RIP) is a heptapeptide that inhibits staphylococcal biofilm formation by obstructing quorum-sensing mechanisms. K4-S4(1-13)a is a 13-residue dermaseptin derivative (DD13) believed to kill bacteria via membrane disruption. We tested each of these peptides as well as a hybrid construct, DD13-RIP, for their ability to inhibit bacterial proliferation and suppress quorum sensing in vitro and for their efficacy in preventing staphylococcal infection in a rat graft infection model with methicillin-resistant Staphylococcus aureus (MRSA) or S. epidermidis (MRSE). In vitro, proliferation assays demonstrated that RIP had no inhibitory effect, while DD13-RIP and DD13 were equally effective, and that the chimeric peptide but not DD13 was slightly more effective than RIP in inhibiting RNA III synthesis, a regulatory RNA molecule important for staphylococcal pathogenesis. In vivo, the three peptides reduced graft-associated bacterial load in a dose-dependent manner, but the hybrid peptide was most potent in totally preventing staphylococcal infections at the lowest dose. In addition, each of the peptides acted synergistically with antibiotics. The data indicate that RIP and DD13 act in synergy by attacking bacteria simultaneously by two different mechanisms. Such a chimeric peptide may be useful for coating medical devices to prevent drug-resistant staphylococcal infections.


* Corresponding author. Mailing address: Amram Mor, Laboratory of Antimicrobial Peptides Investigation, Department of Food Engineering & Biotechnology, Technion-Israel Institute of Technology, Haifa 32000, Israel. Phone: (972) 4-829-3340. Fax: (972) 4-832-0742. E-mail: amor{at}tx.technion.ac.il. Naomi Balaban, Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Phone: (972) 3-640-5137. E-mail: naomibalaban{at}yahoo.com.


Antimicrobial Agents and Chemotherapy, July 2004, p. 2544-2550, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2544-2550.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.